Strong interest in Ortoma's new 3D modelling concept

Report this content

 

Ortoma AB (publ) (”Ortoma” or the ”Company”) today announces that the Company's proof-of-concept presentations of the new technology for converting 2D x-ray images into 3D models, in conjunction with the annual meeting of the American Association of Hip and Knee Surgeons ("AAHKS"), were very successful. The Annual Meeting, which brings together leading orthopedic professionals, was held in Dallas, USA on 4-5 November 2022.

 

 

Ortoma announced on October 31, 2022, that the Company would present a proof-of-concept solution for converting 2D x-ray images into 3D models built on the Company's unique AI-based preoperative planning platform in conjunction with the AAHKS Annual Meeting on November 4-5, 2022.

 

Linus Byström, CEO of Ortoma, comments:

”We are pleased by the tremendous interest from leading executives of the MedTech industry during our visit to Dallas. The feedback confirmed the market need for image conversion of 2D x-ray into 3D models. This sets the stage for next steps of developing our concept into a first 2D to 3D solution in 2024. The 2D to 3D platform will complement and strengthen our existing offering and proceed in parallel with our commercialization of the CT-based OTS-platform."

This proof-of-concept work was initiated when the Company identified a strong need in the market which Ortoma has the unique capability to address. As Ortoma has already developed an advanced machine learning platform, the Company saw an additional opportunity to convert x-ray images into 3D models. The current technology for producing 3D models of, for example, knees and hips is done using a CT scan.  While not all hospitals are equipped with a CT scan, conventional X-rays are usually available. Ortoma will now take advantage of this opportunity and develop the concept into a prototype with the goal of launching a first product in 2024 in parallel with commercializing the CT-based OTS-platform.  

 

Ortoma – Improved Performance

 

 

For further information please contact:

Ortoma CEO Linus Byström

e-mail: info@ortoma.com

 

 

About Ortoma AB (publ)
Ortoma AB develops surgical systems for the planning and positioning of implants in hip, knee and spinal surgery. The purpose of the company’s surgical system, Ortoma Treatment Solution™ (OTS) is to enable surgeons to accurately measure and plan 3D surgery for the placement of joint implants, and during surgery, to optimally position the implant in the patient. Ortoma’s surgical system is aimed at providing better patient outcomes, fewer complications and less follow-up surgeries – and thus better long-term survival rates for implants. OTS is a system that is easily integrated into the processes and routines currently used in surgery, thereby increasing efficiency. Globally, more than 7.5 million orthopedic procedures are performed each year where OTS could be used in hip, knee and spinal surgery. In Sweden, around 42,000 surgical procedures were performed last year, involving hip, knee or spinal surgery. Ortoma’s B shares are listed on Spotlight Stock Market.